Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil VSports app下载. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. V体育官网.

. 2016 Nov;12(5):3045-3050.
doi: 10.3892/ol.2016.5110. Epub 2016 Sep 9.

"VSports在线直播" The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC

Lei Li  1 , Guo-Dong Zhao  1 , Zhe Shi  1 , Li-Li Qi  1 , Li-Yuan Zhou  1 , Ze-Xian Fu  1
Affiliations

The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC

"V体育安卓版" Lei Li et al. Oncol Lett. 2016 Nov.

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide and has a very poor prognosis. Its occurrence has been on the increase in recent years. Surgical resection and liver transplantation are the primary methods of treatment for HCC patients, but can only be applied to 15% of patients. The median survival time of unresectable or metastasizing HCC patients is only a few months. Existing systemic treatment methods are not effective for advanced HCC patients and a new method of treatment is needed for these patients. It has been established that the HCC occurs in multiple stages, however, the pathogenesis at a molecular level is not clear and many key factors are yet to be determined. In the past 30 years, it has become evident that the Ras/Raf/MEK/extracellular signal-regulated kinase (ERK) signaling pathway plays a significant role in the occurrence and development of HCC. This review focused on the association between the Ras/Raf/MEK/ERK signaling pathway and HCC. VSports手机版.

Keywords: MEK; Raf; Ras; extracellular signal-regulated kinase; hepatocellular carcinoma. V体育安卓版.

PubMed Disclaimer

References

    1. Guthle M, Dollinger MM. [Epidemiology and risk factors of hepatocellular carcinoma] Radiologe. 2014;54:654–659. - PubMed (VSports注册入口)
    1. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology. 2000;31:1019–1021. doi: 10.1053/he.2000.6959. - DOI (V体育官网) - PubMed
    1. Abou-Alfa GK. Current and novel therapeutics for hepatocellular carcinoma. In: Perry MC, editor. American Society of Clinical Oncology Educational Book. ASCO; Alexandria, VA: 2004. pp. 192–197.
    1. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR, Hayashi N. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer Am Cancer Soc. 2003;97:3017–3026. - PubMed
    1. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19. doi: 10.1186/1471-230X-3-19. - VSports app下载 - DOI - PMC - PubMed